Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2021

View Archived Issues

Bacteriophage endolysin LysECD7 shows promising antibiofilm activity

Celgene opens enrollment in phase I study of CC-90011 in metastatic CRPC

Biodegradable polymeric solid implants developed for long-acting HIV pre-exposure prophylaxis

Lethal autoinflammatory syndrome linked to loss-of-function C2orf69 gene variants

Dosing begins in phase I study of HLX-04-O in China

Medshine Discovery patents new compounds for NASH

Tecnimede-Sociedade Tecnico-Medicinal discloses compounds for tuberculosis

Wigen Biomedicine Technology presents GTPase KRAS mutant inhibitors

Latvian Institute of Organic Synthesis discloses tubulin polymerization inhibitors

First participants dosed in phase Ib/IIa FOCUSC9 study of WVE-004

NIMIUM and Paraza partner to develop G3PP activators to treat cardiometabolic diseases

Updated interim data from ongoing phase I/IIa study of OpRegen in dry AMD with GA

Lantern reports promising new preclinical data for LP-184 in pancreatic cancer

CA-125 is a diagnostic marker of tuberculosis in patients without HIV

Affinia and IOB collaborate to design novel CNS promoters for gene therapy

German clearance for phase I/IIa study of HDP-101 in multiple myeloma

Poor sleep quality in people with HIV is linked to lower CSF Abeta42 levels

Rab35-silencing as new strategy to impair HIV propagation

IL-12 and IL-18 are highly secreted in patients with HIV/TB coinfection

FDA clears IND for phase I/II trial of ExoFlo to treat post-acute COVID-19 syndrome

DSMB recommends continuation of phase II trial of ANVS-401 in Alzheimer's disease

All together now: Cure research plays big role at IAS 2021

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...